Navigation Links
U of M begins nation's first clinical trial using T-reg cells from cord blood in leukemia treatment
Date:9/5/2007

afterbirth after the birth of a child) because they occur in higher frequency than what is typically found in most adults and are easier to expand in culture prior to treatment. This is the first human clinical trial in the world that uses T-regs derived from umbilical cord blood.

This trial is designed to find the highest possible safe dose of T-regs in immune suppressed patients undergoing a double umbilical cord blood transplant for leukemia, other blood cancer, or bone marrow failure. From data in animal models, University researchers believe there will be no acute side effects with the T-regs.

If the data in humans mimics animal models, T-regs will be a powerful therapy to prevent GVHD and enhance engraftment in transplant patients. Once safety and efficacy data are known, researchers hope to test T-regs for treatment of various autoimmune diseases, such as type I diabetes and multiple sclerosis. University researchers hypothesize that if T-regs are transplanted early in the life of the disease, the cells may help prevent disease progression.

This is an exciting time. In the near future, I anticipate being able to combine immune cell populations, like T-regs, that stop immune reactions responsible for autoimmune diseases like diabetes, and immune responses to stem cell infusion given to repair already damaged tissues. This brings great hope not only for adults and children with cancer but many other diseases as well. At the close of this clinical trial, we hope to go right to our first clinical trial with T-regulatory cells in the treatment of newly diagnosed diabetes, said John E. Wagner, M.D., director of the pediatric hematology-oncology and blood and marrow transplantation program at the University of Minnesota.


'/>"/>

Contact: Molly Portz
mportz@umn.edu
612-625-2640
University of Minnesota
Source:Eurekalert

Page: 1 2

Related biology news :

1. International trial of two microbicides begins
2. NIAID begins clinical trial of West Nile virus vaccine
3. EuroVacc 02 HIV Vaccine Trial Begins
4. Wyoming cloud seeding experiment begins this month
5. Cancer scientists create human leukemia process to map how disease begins, progresses
6. Parents need to be educated about HPV vaccinations for daughters
7. Simple idea to dramatically improve dengue vaccinations
8. Novel therapy combinations gain ground in treating hepatitis
9. New study suggests promising drug combinations for sleeping sickness
10. Failure to meet United Nations sanitation target could affect millions of the worlds poorest
11. Effect on breast tumors of DNA alternations in 3 genes described
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... Valid S.A. ("Company") (BM&FBOVESPA: VLID3 ON), is pleased to ... State of Washington,s Department of Licensing, in ... central issuance system for driver,s licenses and identification cards to ... and development will start in January 2015, with enrollment and ...
(Date:1/22/2015)... , Jan. 13, 2015 Technology Showcase, Hall E ... identity authentication solutions, today announced it will showcase its EyeLock ... developed by the Department of Energy,s Oak Ridge National ... Auto Show . EyeLock,s iris identity authentication technology is being ...
(Date:1/22/2015)... Inc. (NASDAQ: NXTD and NXTDW) a biometric authentication company ... of the Wocket™ smart wallet at CES 2015 in Las ... one of the "11 Hot Products at CES" in a review published ... Far" by Newseveryday.com and "The top 10 gadgets from CES 2015" by ...
Breaking Biology News(10 mins):Valid USA Signs Contract For Washington Driver's License Issuance 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 2EyeLock Debuts First Iris Authentication Technology Embedded in 3D Printed Automobile 3CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3
... head impact injury are an interesting scientific question. Professor ... for Biomechanics and Mechanobiology of the Ministry of Education, ... and the School of Materials Science and Engineering, Wuhan ... After 3 years of innovative research, they are making ...
... to achieve goals set by the federal government for reducing ... need to eliminate an average of 64 excess calories per ... American Journal of Preventive Medicine . This reduction could ... both. Without this reduction, the authors predict that the average ...
... Ill. -- Researchers have determined that bacteria are present ... the common belief that normal urine is sterile. These ... Journal of Clinical Microbiology by researchers at ... "Doctors have been trained to believe that urine is ...
Cached Biology News:Mechanical properties and microstructure of cranial and beak bones of the woodpecker and the lark 2How many calories does it take to reach childhood obesity prevention goals? 2How many calories does it take to reach childhood obesity prevention goals? 3Loyola study debunks common myth that urine is sterile 2
(Date:2/27/2015)... 27, 2015 Immunovaccine Inc. (“Immunovaccine”) ... company, today announced that the U.S. Food and ... Track designation and Phase I clinical trials of ... the mutual co-development agreement signed with Gilead Life ... designation for the DPX-Survivac. , “We have been ...
(Date:2/27/2015)... 2015 FamilyFarms Group is pleased to ... State Line Farms, received the 2015 Tomorrow’s Top Producer ... the age of 35, who has demonstrated excellence in ... to win the Tomorrow's Top Producer Horizon Award. Every ... Top Producer Award and learning from their experiences. It ...
(Date:2/26/2015)... 26, 2015 S&P Capital IQ (MHFI) announced ... coverage on MabVax Therapeutics Holdings Inc . ... stage biotechnology company focused on the development of vaccine ... the treatment of cancer. MabVax has discovered a pipeline ... immune responses generated by patients who have been immunized ...
(Date:2/26/2015)... 26, 2015   Synageva BioPharma Corp. ... developing therapeutic products for rare disorders, today reported ... goals, other key objectives, and financial guidance.  Synageva,s ... at 4:30 p.m. EST to review the financial ... participate in today,s call by telephone, please dial ...
Breaking Biology Technology:Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 2Immunovaccine Inc. (TSX: IMV) receives Fast Track and Phase I trial approval for Ebola and Anthrax vaccine programs, signs co-development agreement with Gilead Sciences 3Matt Sims Receives the 2015 Tomorrow’s Top Producer Horizon Award 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 2S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 3S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 4S&P Capital IQ Initiates Coverage on MabVax Therapeutics Holdings Inc. in S&P Capital IQ Factual Stock Reports 5Synageva BioPharma Reports 2014 Full Year Financial Results 2Synageva BioPharma Reports 2014 Full Year Financial Results 3Synageva BioPharma Reports 2014 Full Year Financial Results 4Synageva BioPharma Reports 2014 Full Year Financial Results 5Synageva BioPharma Reports 2014 Full Year Financial Results 6Synageva BioPharma Reports 2014 Full Year Financial Results 7Synageva BioPharma Reports 2014 Full Year Financial Results 8Synageva BioPharma Reports 2014 Full Year Financial Results 9
... Inc.,(Nasdaq: ENMD ), a clinical-stage pharmaceutical ... and inflammatory diseases, today,announced that the U.S. ... its,Investigational New Drug (IND) application for its ... ), ENMD-2076 is a novel, ...
... Cinpathogen, through its,partnership in the Fudan-Cinpathogen Clinical and ... consulting,services to Shanghai area hospitals. For the past ... the Center has diagnosed and characterized over 3000,cases ... area,hospitals and colleagues at Fudan University, the University ...
... N.C., Jan. 3 Chimerix, Inc., a,biotechnology company ... Frazer, M.B., Ch.B., FRCA, FFPM has joined the,company ... Chimerix, Dr. Frazer served as the Chief Medical,Officer ... Medical) where he was responsible for the design ...
Cached Biology Technology:EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076 2EntreMed Announces FDA Acceptance of IND Application for Aurora Kinase/Angiogenesis Inhibitor, ENMD-2076 3Cinpathogen Provides Clinical Diagnostic Consulting Services to Shanghai Area Hospitals 2Chimerix Appoints Neil Frazer, M.B., Ch.B., FRCA, FFPM as Chief Medical Officer 2
The product contains 2 ml Dynabeads® Epoxy (4.5 μm). Supplied at 4 x 10e8 beads/ml...
PFK-2 car (P-17)...
... ml Dynabeads Epoxy (4.5 m). Hydrophobic ... groups. Ideal for coupling of antibodies for ... initial coupling with covalent binding of primary ... groups (SH)) occurring within 16-20 hours. Coupling ...
LTBP-2 (7B10)...
Biology Products: